Design, synthesis and biological evaluation of benzoyl hydrazone derivatives as anticancer agents inducing...

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Cancer remains a significant global health challenge due to high mortality and chemotherapy toxicity.
• Developing novel, effective, and less toxic anticancer agents is crucial.

Purpose of the Study:

• To design and synthesize novel benzoyl hydrazone derivatives for potential anticancer activity.
• To identify potent anticancer candidates through molecular hybridization.

Main Methods:

• Synthesis of 16 benzoyl hydrazone derivatives.
• In vitro antiproliferative assays against human cancer cell lines.
• Cytotoxicity assessment on non-cancerous cells.
• Mechanistic studies including ROS, mitochondrial membrane potential, and caspase activity assays.
• Immunofluorescence analysis for microtubule disruption.

Main Results:

• Compound Q-11 demonstrated significant antiproliferative activity (IC50 = 12.5 nM) against SGC-7901 gastric cancer cells.
• Q-11 exhibited broad-spectrum inhibition across multiple cancer cell lines.
• Q-11 showed lower cytotoxicity towards non-cancerous HK-2 renal cells, indicating good selectivity.
• Mechanistic studies revealed Q-11 induces ROS accumulation, mitochondrial depolarization, and caspase-dependent apoptosis.
• Q-11 treatment led to significant microtubule disruption.

Conclusions:

• Compound Q-11 is a highly potent anticancer lead with nanomolar activity.
• Q-11's mechanism involves ROS induction, mitochondrial dysfunction, apoptosis, and microtubule disruption.
• Q-11 presents a promising candidate for further anticancer drug discovery and development.